Selank and Semax are two synthetic neuropeptides developed in Russia and widely studied as nootropic research compounds in preclinical neuroscience. Both emerged from work at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are designed as stabilized analogues of endogenous peptide sequences. Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, while Semax is a synthetic analogue of a fragment of adrenocorticotropic hormone — specifically the ACTH(4-10) region. This guide examines what is known about each compound from animal-model and in-vitro literature, how they compare at the molecular level, and how research-grade material is handled and verified in the laboratory.
These peptides are sold and discussed here strictly as laboratory reference materials. Nothing below describes human or animal use; all effects are framed in the context of published preclinical research.
In the research literature, a neuropeptide is a short chain of amino acids that acts as a signalling molecule in the nervous system — modulating neurotransmission, gene expression, or trophic support rather than serving a structural or metabolic role. Endogenous neuropeptides such as oxytocin, substance P, and the ACTH/melanocortin family operate at very low concentrations and often produce effects that outlast their brief presence in tissue, a phenomenon sometimes described as a neuropeptide's "memory" in the signalling cascade it triggers.
The term nootropic entered the scientific vocabulary through Corneliu Giurgea in the 1970s and originally described compounds proposed to support learning and memory processes while exhibiting low toxicity. In a strict research context, calling a compound a "nootropic candidate" is a statement about the category of questions investigators ask of it — effects on learning paradigms, synaptic plasticity markers, neurotrophin expression — not a claim that the compound improves cognition in people. Selank and Semax sit in this investigational category: they are studied with the experimental tools of cognitive and behavioural neuroscience, in models, without established human cognitive indications outside the regulatory frameworks of their country of origin.
Two structural ideas recur across this class and are worth fixing before looking at each peptide individually:
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its first four residues correspond to tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) released from the Fc region of immunoglobulin G that has long been studied for its immunomodulatory and phagocytosis-stimulating activity. The appended Pro-Gly-Pro tail is the stabilizing modification described above.
Because Selank inherits tuftsin's sequence, the preclinical literature on it spans two domains that are not usually examined together. On the neuromodulatory side, animal-model studies have investigated Selank for anxiolytic-type behavioural profiles, examining its interaction with GABAergic and serotonergic systems and reporting changes in markers associated with these pathways. Several rodent studies have looked at Selank's influence on the expression of brain-derived neurotrophic factor (BDNF) and on the balance of monoamine metabolism in specific brain regions. On the immunological side, consistent with its tuftsin lineage, Selank has been studied for effects on cytokine balance and the expression of immune-signalling genes.
A recurring theme in Selank research is the absence of the sedation and dependence liability that characterise classical benzodiazepine GABA-A modulators in the same animal paradigms — which is precisely why investigators have found it an interesting probe of anxiolytic-type signalling without that pharmacological baggage. This is a description of how the compound behaves in models, not a statement about clinical outcomes.
The tuftsin connection is not a footnote — it is the reason Selank's research profile bridges neuroscience and immunology. Tuftsin receptors and tuftsin-responsive pathways exist outside the classic neurotransmitter framework, so Selank is sometimes studied as a tool for asking how immune signalling and central nervous system signalling intersect. For a laboratory characterising the compound, this dual heritage is the single most useful fact to keep in view when interpreting heterogeneous published results.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its first four residues correspond to the ACTH(4-10) fragment Met-Glu-His-Phe — the portion of adrenocorticotropic hormone associated with neurotropic and behavioural activity rather than with the hormone's steroidogenic (cortisol-releasing) function. As with Selank, the native fragment is extended with a Pro-Gly-Pro tail to resist degradation. The result is a molecule that retains the central-nervous-system-relevant portion of the ACTH/melanocortin signal while shedding the endocrine activity of the full hormone.
The dominant theme in Semax research is neurotrophic signalling. Multiple cell-culture and rodent studies have investigated Semax in connection with brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), and with the downstream signalling these neurotrophins engage — including pathways associated with neuronal survival and the TrkB receptor system. Semax has been examined in models of cerebral ischemia and other forms of neuronal stress as a tool for studying neuroprotection, with reported effects on expression of neurotrophins and their receptors in affected tissue. Other preclinical work has profiled Semax against markers of the brain-derived neurotrophic factor cascade and oxidative-stress response in nervous tissue.
Like Selank, Semax is studied for behavioural correlates in learning and attention paradigms in animals. The mechanistic centre of gravity, however, is clearly the neurotrophin axis — when researchers reach for Semax, the question on the bench is usually about BDNF/NGF signalling and neuronal resilience in a model system.
Selank and Semax are routinely discussed side by side, and the reasons are structural and historical rather than marketing convenience. Both were developed by the same Russian research lineage; both are heptapeptides; both are analogues of endogenous regulatory peptides; and both use the identical Pro-Gly-Pro stabilization strategy. That shared design language is why a laboratory stocking one very often stocks the other, and why protocols for handling them are nearly interchangeable.
Their divergence is in lineage and pathway, and that divergence is the genuinely useful comparison. Selank descends from an immunomodulatory peptide and is studied across GABA/serotonin and immune signalling; Semax descends from a pituitary hormone fragment and is studied predominantly for neurotrophic (BDNF/NGF) signalling. Investigators sometimes study them together precisely because they probe different nodes of nervous-system regulation while sharing a common pharmacological scaffold — making them a natural pair for comparative research questions.
The table below summarises the contrast at the level most relevant to characterisation and study design.
| Attribute | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin (Thr-Lys-Pro-Arg), an IgG-derived immunomodulatory tetrapeptide | ACTH(4-10) (Met-Glu-His-Phe), a fragment of adrenocorticotropic hormone |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (heptapeptide) | Met-Glu-His-Phe-Pro-Gly-Pro (heptapeptide) |
| Peptide class | Synthetic tuftsin analogue / regulatory neuropeptide | Synthetic ACTH(4-10) analogue / melanocortin-related neuropeptide |
| Primary research pathway | GABAergic & serotonergic modulation; BDNF expression; immune/cytokine signalling | BDNF/NGF neurotrophic signalling; TrkB-associated pathways; neuroprotection |
| Research focus | Anxiolytic-type behavioural models; neuroimmune intersection | Neuroprotection and neurotrophin expression in stress/ischemia models; learning paradigms |
| Stabilizing modification | C-terminal Pro-Gly-Pro | C-terminal Pro-Gly-Pro |
| Common model delivery route | Intranasal (research parameter) | Intranasal (research parameter) |
Research-grade Selank and Semax are supplied as a lyophilised (freeze-dried) powder, typically as the acetate salt, sealed in a vial under conditions that minimise exposure to moisture and oxygen. Lyophilisation is what makes peptides shippable and shelf-stable: removing water suppresses the hydrolytic and microbial processes that would otherwise degrade the chain. The following points describe handling at the laboratory level, for qualified personnel working with reference materials — they are not, and must not be read as, instructions for administration to humans or animals.
Model delivery route. Both peptides appear in the literature predominantly via the intranasal route in animal studies, a choice driven by the research rationale that intranasal delivery can model access to the central nervous system while bypassing first-pass metabolism. In the context of this article, "intranasal" is a description of how published experiments were conducted — a research route only. It is not a recommendation, protocol, or instruction for any human use.
Reconstitution (bench preparation of a stock solution). Lyophilised peptide is typically dissolved for in-vitro or model work using bacteriostatic water or another appropriate solvent selected for the assay, added slowly down the inner wall of the vial rather than directly onto the powder, and allowed to dissolve without vigorous agitation. Peptides are sensitive to mechanical shear and to extremes of pH; gentle swirling rather than vortexing preserves chain integrity. The specific solvent, concentration, and buffer are dictated by the experimental design and the analytical method downstream.
Storage. As supplied, sealed lyophilised peptide is generally held frozen for long-term storage and kept away from light and humidity. Once reconstituted, peptide solutions are far less stable and are typically kept refrigerated and used within a short, study-defined window; repeated freeze-thaw cycles are minimised because each cycle can degrade peptide and aggregate material. Aliquoting a stock into single-use fractions before freezing is the standard way labs avoid repeated thawing. Cold-chain discipline from manufacture through delivery to bench storage is a core determinant of whether the material on the bench still matches its Certificate of Analysis.
For any peptide used as a research reference material, identity and purity are the entire value proposition — a behavioural or biochemical result is only interpretable if the compound in the vial is what the label says, at a known purity. Two analytical anchors establish this.
High-Performance Liquid Chromatography (HPLC) is the standard method for quantifying peptide purity. In a typical reversed-phase HPLC run, the peptide is separated from synthesis-related impurities — truncated sequences, deletion products, and residual reagents — and purity is reported as the percentage of total peak area attributable to the target peptide. Research-grade Selank and Semax are commonly characterised to ≥98% HPLC purity; the chromatogram itself, not just the headline number, is the primary evidence. Mass spectrometry is frequently paired with HPLC to confirm the molecular weight and therefore the identity of the sequence.
A Certificate of Analysis (COA) is the document that ties a specific physical batch to its analytical results. A meaningful COA is batch-specific — keyed to the lot number on the vial — and reports the measured purity, the analytical methods used, and the confirmed identity of the compound. A generic certificate that is not tied to the lot in hand tells a laboratory very little. When evaluating a supplier, the questions that matter are concrete: Is the COA specific to this batch? Does it include the HPLC chromatogram and a mass-spec identity confirmation? Does the reported purity meet the threshold the study requires?
They are distinct compounds that share a design philosophy. Both are synthetic heptapeptides built from an endogenous parent sequence plus a stabilizing Pro-Gly-Pro tail, and both came from the same Russian research lineage. They differ in origin and pathway: Selank is a tuftsin analogue studied across GABA/serotonin and immune signalling, while Semax is an ACTH(4-10) analogue studied mainly for BDNF/NGF neurotrophic signalling. They are grouped together because of their shared scaffold, not because they are interchangeable.
Semax incorporates the ACTH(4-10) fragment — the Met-Glu-His-Phe sequence — which is the region of adrenocorticotropic hormone associated with neurotropic and behavioural activity rather than with cortisol release. By using only this fragment plus a Pro-Gly-Pro extension, Semax is studied as a tool that engages the central-nervous-system-relevant portion of the ACTH/melanocortin signal without the steroidogenic endocrine activity of the intact hormone.
The C-terminal Pro-Gly-Pro (PGP) extension is a stabilizing modification. Native tuftsin and the bare ACTH(4-10) fragment are degraded rapidly by peptidases, which makes them difficult to study. Appending PGP — itself a regulatory peptide — slows enzymatic cleavage and lengthens the experimental window, which is the core reason these analogues are tractable in research where the parent sequences are not.
In the preclinical literature, Selank is most associated with GABAergic and serotonergic modulation, BDNF expression, and immunomodulatory (cytokine) signalling, reflecting its tuftsin origin. Semax is most associated with BDNF and NGF neurotrophic signalling, TrkB-related pathways, and neuroprotection in cell and rodent stress models, reflecting its ACTH(4-10) origin. The two probe different regulatory nodes of the nervous system.
Purity is verified by High-Performance Liquid Chromatography (HPLC), which separates the target peptide from synthesis impurities and reports purity as a percentage of total peak area, typically ≥98% for research-grade material. Mass spectrometry confirms molecular weight and identity. These results should appear on a batch-specific Certificate of Analysis keyed to the lot number on the vial.
Alluvia Peptides supplies Selank and Semax as lyophilised research reference materials for laboratory use only. Every batch is HPLC-verified to ≥98% purity, ships with a batch-specific Certificate of Analysis that includes the analytical methods and identity confirmation, and is handled under cold-chain conditions from synthesis through delivery to preserve integrity. For investigators characterising these nootropic neuropeptides, the COA and chromatogram are available per lot so the material on your bench is traceable to its analytical record.
Research use only — not for human consumption. The information in this article is provided strictly for educational and scientific reference. Selank and Semax are sold as laboratory research materials and are not intended for human or animal consumption, nor for any diagnostic, therapeutic, or clinical use. They are not drugs, dietary supplements, or medical devices, and nothing here should be interpreted as medical advice or as a recommendation to administer these compounds to humans or animals. All described effects refer to published preclinical (in-vitro and animal-model) research. Handling of these materials should be restricted to qualified personnel in an appropriately equipped laboratory, in compliance with all applicable laws and institutional regulations.